Diabetic Neuropathy - Pipeline Review, H1 2017

Transcription

1 Diabetic Neuropathy - Pipeline Review, H1 2017

2 Diabetic Neuropathy - Pipeline Review, H BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers. We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use How To Buy information on the last page of this document. We look forward to being of service to you. If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf. Phone: +44 (0) or reportstore@bioportfolio.com 2

3 Diabetic Neuropathy - Pipeline Review, H Diabetic Neuropathy - Pipeline Review, H Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Neuropathy - Pipeline Review, H1 2017, provides an overview of the Diabetic Neuropathy (Metabolic Disorders) pipeline landscape. Diabetic neuropathy, a common complication of diabetes, is damage to the nerves that allow feeling things such as pain. Symptoms include tingling, numbness, burning and pain. The predisposing factors are obesity, hypertension, high lipid and sugar levels, smoking, etc. It may be managed by medication and dietary modification. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diabetic Neuropathy - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Diabetic Neuropathy (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Diabetic Neuropathy (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Neuropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 5, 3, 16 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively. Diabetic Neuropathy (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Neuropathy (Metabolic Disorders). - The pipeline guide reviews pipeline therapeutics for Diabetic Neuropathy (Metabolic Disorders) by companies 3

4 and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from preregistration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Diabetic Neuropathy (Metabolic Disorders) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Diabetic Neuropathy (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Neuropathy (Metabolic Disorders) Reasons to buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Diabetic Neuropathy (Metabolic Disorders). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it s most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Diabetic Neuropathy (Metabolic Disorders) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline. Additional Details Publisher : Global Markets Direct Reference : GMDHC9355IDB Number of Pages : 106 Report Format : PDF Publisher Information : 4

5 5

6 Table Of Contents for Diabetic Neuropathy - Pipeline Review, H [Report Updated: ] Table of ContentsList of TablesList of FiguresIntroductionGlobal Markets Direct Report CoverageDiabetic Neuropathy - OverviewDiabetic Neuropathy - Therapeutics DevelopmentPipeline OverviewPipeline by CompaniesPipeline by Universities/InstitutesProducts under Development by CompaniesProducts under Development by Universities/InstitutesDiabetic Neuropathy - Therapeutics AssessmentAssessment by TargetAssessment by Mechanism of ActionAssessment by Route of AdministrationAssessment by Molecule TypeDiabetic Neuropathy - Companies Involved in Therapeutics DevelopmentAchelios Therapeutics IncAngelini GroupApollo Endosurgery IncAraim Pharmaceuticals IncCelgene CorpCommence Bio IncGrunenthal GmbHKineta IncKPI Therapeutics IncMedifron DBT Co LtdNeuralstem IncNovaLead Pharma Pvt LtdOmeros CorpReata Pharmaceuticals IncRelief Therapeutics Holding AGViroMed Co LtdDiabetic Neuropathy - Drug ProfilesA Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressAAD Drug ProfileProduct DescriptionMechanism Of ActionR&D Progressatexakin alfa - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressBNV Drug ProfileProduct DescriptionMechanism Of ActionR&D Progresscibinetide - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressCMB Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressCNV Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressCyndacel-M - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressGene Therapy to Activate NGF for Diabetic Neuropathy and Peripheral Nerve Injury - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressKCP Drug ProfileProduct DescriptionMechanism Of ActionR&D Progressketoprofen - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressKU-32 - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressLpathomab - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressMDR Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressMDR Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressMonoclonal Antibodies to Inhibit MASP-2 for Diabetic Complications and Rheumatoid Arthritis - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressNLP Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressNSI Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressNSI Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressOMS Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressPDA Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressPeptide to Activate G Protein-Coupled Receptor Mas for Cardiovascular, Metabolic Disorders and Male Health - Drug ProfileProduct DescriptionMechanism Of ActionR&D Progresspirenzepine hydrochloride - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressRTA Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressSmall Molecules for Diabetic Neuropathy - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressSmall Molecules for Pain - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressSmall Molecules to Inhibit Hsp90 for Peripheral Neuropathy and Neurodegenerative Disorders - Drug ProfileProduct DescriptionMechanism Of ActionR&D Progresstrazodone hydrochloride - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressU Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressVM Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressXK-568b - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressDiabetic Neuropathy - Dormant ProjectsDiabetic Neuropathy - Discontinued ProductsDiabetic Neuropathy - Product Development MilestonesFeatured News & Press ReleasesSep 08, 2016: ViroMed proceeding with the World s first phase III gene therapy clinical trial for diabetic peripheral neuropathyjun 27, 2016: VM BioPharma Announces First Patient Dosed in Phase 3 Study of Gene Therapy Candidate, VM202, in Painful Diabetic Peripheral NeuropathyMar 06, 2015: ViroMed dba VM BioPharma: A Phase II Study Done at Northwestern Hospital Shows Potential Relief for Diabetics with Painful ConditionSep 23, 2013: Lpath Awarded NIH SBIR Grant for LpathomabMar 18, 2011: ViroMed Enrolls Final Patient For US VM202-DPN Phase I/II Clinical TrialMar 04, 2009: ViroMed Receives Approval from US FDA for Phase I/II Trial for Diabetic NeuropathyAppendixMethodologyCoverageSecondary ResearchPrimary ResearchExpert Panel ValidationContact UsDisclaimer 6

7 How to Buy... Diabetic Neuropathy - Pipeline Review, H [Report Updated: ] Option 1 - Online Go to our website and pay online with any major debit or credit card: Option 2 - Request a Proforma Invoice Fill in the details below, and either Scan this page and it to us at reportstore@bioportfolio.com or Fax it to us at +44 (0) We will send you a Proforma Invoice and deliver your report on settlement. Your Name: Job Title: Your Your Contact Phone: Company Name: Address: Post/Zip Code: Country: P.O. Number: Any Other Instructions: Pricing Options: (please tick one) $2000 Single User Price $4000 Site License Price $6000 Enterprise License Price Payment Options: (please tick one) Online Credit Card (we will you the invoice with a payment link) Direct Wire Transfer (we will you the invoice with our bank details) Authorising Signature: Option 3 - Phone Us on +44 (0) We will be delighted to give you our personal attention. 7